Skip to main content
Fig. 3 | Genome Medicine

Fig. 3

From: Small-molecule MMP2/MMP9 inhibitor SB-3CT modulates tumor immune surveillance by regulating PD-L1

Fig. 3

Immune features in tumors for B16F10 xenograft mouse model with SB-3CT treatment. a Fluorescence expression and b quantification of CD8+ T cells. c Heatmap of Z-score normalized percentage of immune cell populations (dh) in TILs for B16F10 tumor-bearing mice treated with anti-PD-1 and SB-3CT in combination or alone. dh In the implanted B16F10 tumors from mice treated with or without SB-3CT and PD-1 blockade, fluorescence-activated cell sorting (FACS) was used to measure d CD8+ in CD3+ T cells, e CD8+ IFNγ+ in CD8+ T cells, f CD8+ GZMB+ in CD8+ T cells, g Gr-1+ CD11b+ MDSCs in CD45+ cells, and h CD25+ FOXP3+ Treg in CD4+ cells. i Fluorescence expression and j quantification of PD-L1 in B16F10 tumor-bearing wild-type C57/BL6 mice treated with isotype, SB-3CT, anti-PD-1, or combination strategy. Sample size is 5 in each cohort. Scale bars, 50 μm. Results are mean ± s.d. ns, p > 0.05,*p < 0.05, **p < 0.01, and ***p < 0.001, as determined by one-way ANOVA and Dunnett’s multiple comparison test

Back to article page